These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 22801669)

  • 1. T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
    Bollard CM; Rooney CM; Heslop HE
    Nat Rev Clin Oncol; 2012 Sep; 9(9):510-9. PubMed ID: 22801669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.
    Hong J; Ni J; Ruan M; Yang M; Dong Q; Li Q
    Int J Hematol; 2020 Jun; 111(6):851-857. PubMed ID: 32162095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.
    Heslop HE; Savoldo B; Rooney CM
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):401-13. PubMed ID: 15498712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.
    Rouce RH; Louis CU; Heslop HE
    Curr Opin Hematol; 2014 Nov; 21(6):476-81. PubMed ID: 25159713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
    Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide.
    Terao T; Tsushima T; Fukumoto A; Kuzume A; Miura D; Narita K; Takeuchi M; Matsue K
    Int J Hematol; 2021 Jul; 114(1):136-140. PubMed ID: 33675520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
    Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
    Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
    Tse E; Kwong YL
    Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
    Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L
    Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
    Papalexandri A; Gavriilaki E; Vardi A; Kotsiou N; Demosthenous C; Constantinou N; Touloumenidou T; Zerva P; Kika F; Iskas M; Batsis I; Mallouri D; Yannaki E; Anagnostopoulos A; Sakellari I
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.